Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.
from USATODAY - News Top Stories https://ift.tt/84vaWp3
via
Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.